Gut microbiota in the pathogenesis of inflammatory bowel disease

被引：1382

作者：

Nishida A. ^{[1
]}

Inoue R. ^{[2
]}

Inatomi O. ^{[1
]}

Bamba S. ^{[1
]}

Naito Y. ^{[3
]}

Andoh A. ^{[1
]}

机构：

[1] Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu

[2] Laboratory of Animal Science, Department of Agriculture and Life Science, Kyoto Prefectural University, Kyoto

[3] Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto

来源：

Clinical Journal of Gastroenterology | 2018年 / 11卷 / 1期

基金：

日本学术振兴会;

关键词：

Dysbiosis; Fecal microbiota transplantation; Inflammatory bowel disease; Microbiota;

D O I：

10.1007/s12328-017-0813-5

中图分类号：

学科分类号：

摘要：

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic and relapsing inflammatory disorder of the intestine. Although its incidence is increasing globally, the precise etiology remains unclear and a cure for IBD has yet to be discovered. The most accepted hypothesis of IBD pathogenesis is that complex interactions between genetics, environmental factors, and the host immune system lead to aberrant immune responses and chronic intestinal inflammation. The human gut harbors a complex and abundant aggregation of microbes, collectively referred to as the gut microbiota. The gut microbiota has physiological functions associated with nutrition, the immune system, and defense of the host. Recent advances in next-generation sequencing technology have identified alteration of the composition and function of the gut microbiota, which is referred to as dysbiosis, in IBD. Clinical and experimental data suggest dysbiosis may play a pivotal role in the pathogenesis of IBD. This review is focused on the physiological function of the gut microbiota and the association between the gut microbiota and pathogenesis in IBD. In addition, we review the therapeutic options for manipulating the altered gut microbiota, such as probiotics and fecal microbiota transplantation. © 2017, Japanese Society of Gastroenterology.

引用

页码：1 / 10

页数：9

共 109 条

[1]

Kaser A., Zeissig S., Blumberg R.S., Inflammatory bowel disease, Annu Rev Immunol, 28, pp. 573-621, (2010)

[2]

Khor B., Gardet A., Xavier R.J., Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, 7351, pp. 307-317, (2011)

[3]

Kaplan G.G., The global burden of IBD: from 2015 to 2025, Nat Rev Gastroenterol Hepatol, 12, 12, pp. 720-727, (2015)

[4]

Kaplan G.G., Ng S.C., Understanding and preventing the global increase of inflammatory bowel disease, Gastroenterology, 152, 2, pp. 313-321.e2, (2017)

[5]

Liu J.Z., van Sommeren S., Huang H., Et al., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations, Nat Genet, 47, 9, pp. 979-986, (2015)

[6]

Goldsmith J.R., Sartor R.B., The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications, J Gastroenterol, 49, 5, pp. 785-798, (2014)

[7]

Sheehan D., Moran C., Shanahan F., The microbiota in inflammatory bowel disease, J Gastroenterol, 50, 5, pp. 495-507, (2015)

[8]

Honda K., Littman D.R., The microbiome in infectious disease and inflammation, Annu Rev Immunol, 30, pp. 759-795, (2012)

[9]

Qin J., Li R., Raes J., Et al., A human gut microbial gene catalogue established by metagenomic sequencing, Nature, 464, 7285, pp. 59-65, (2010)

[10]

Eckburg P.B., Bik E.M., Bernstein C.N., Et al., Diversity of the human intestinal microbial flora, Science, 308, 5728, pp. 1635-1638, (2005)

← 1 2 3 4 5 6 7 8 9 10 →